AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24355438 — intervention group
Group type: COMPARATOR
Intervention: Protein spread feeding (SD), dietary protein spread over four daily meals
Number of subjects: 66
Study 23318621 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual‐Fracture‐Carving Simulator
Number of subjects: 48
Study 23318621 — intervention group
Group type: COMPARATOR
Intervention: Sawbones
Number of subjects: 48
Study 23318621 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 21502597 — intervention group
Group type: COMPARATOR
Intervention: Huperzine A 200 μg BID
Number of subjects: 210
Study 21502597 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A 400 μg BID
Number of subjects: 210
Study 19841339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride, 2%, with 1:100 000 epinephrine (group 1)
Number of subjects: 140
Study 19841339 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine, 2%, with 1:200 000 epinephrine (group 2)
Number of subjects: 140
Study 16766774 — intervention group
Group type: EXPERIMENTAL
Intervention: Special nutritional supplement providing 90 mg isoflavones, 800 mg calcium, 400 IU vitamin D, 60 ug vitamin K and 31 g proteins per day.
Number of subjects: 0
Study 16766774 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional supplement provided by the Chilean Ministry of Health.
Number of subjects: 0
Study 15120551 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol-string task
Number of subjects: 0
Study 15120551 — intervention group
Group type: COMPARATOR
Intervention: Developmental dyslexic readers
Number of subjects: 0
Study 11115724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus-based quadrivalent vaccine
Number of subjects: 0
Study 11115724 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9543218 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of micronised flavonoid fraction for 2 months
Number of subjects: 895
Study 8224273 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 0
Study 8224273 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2871145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10
Study 2871145 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 10
Study 28580791 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm accelerometer
Number of subjects: 82
Study 26754933 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH) group
Number of subjects: 122
Study 26754933 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) group
Number of subjects: 122
Study 24997093 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 SQ+
Number of subjects: 450
Study 24997093 — intervention group
Group type: EXPERIMENTAL
Intervention: 15,000 SQ+
Number of subjects: 450
Study 24997093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 22921297 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted voice hygiene (VH) program
Number of subjects: 31
Study 22921297 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice hygiene (VH) program plus resonant voice training (VH+VT)
Number of subjects: 31
Study 22921297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 19734790 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg + dexamethasone 8 mg + ketamine (0.15 mg kg(‐1)) + paracetamol 1 g + ketorolac 15 mg
Number of subjects: 42
Study 19734790 — intervention group
Group type: COMPARATOR
Intervention: placebo + paracetamol 1 g + ketorolac 15 mg
Number of subjects: 42
Study 18364384 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise (treatment group; n = 17)
Number of subjects: 27
Study 18364384 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group; n = 10)
Number of subjects: 27
Study 15452357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream adjusted to pH 4.0
Number of subjects: 0
Study 15452357 — intervention group
Group type: COMPARATOR
Intervention: Cream adjusted to pH 7.5
Number of subjects: 0
Study 12417880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 150 microg twice daily, n = 20
Number of subjects: 62
Study 12417880 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 20
Number of subjects: 62
Study 10714780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral buttress plate with anteromedial antiglide plate
Number of subjects: 1
Study 10714780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual buttress construct
Number of subjects: 1
Study 10714780 — intervention group
Group type: COMPARATOR
Intervention: Lateral buttress plate alone
Number of subjects: 1
Study 7532559 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (2 mg/kg)
Number of subjects: 14
Study 1774375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 47
Study 1774375 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 47
Study 6123021 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic methionyl human growth hormone
Number of subjects: 22
Study 6123021 — intervention group
Group type: COMPARATOR
Intervention: Pituitary human growth hormone
Number of subjects: 22
Study 31477688 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional polygenic risk scores (PRSs) created using gene set enrichment analysis applied to meta-GWAS data
Number of subjects: 515
Study 28422968 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care (POC) device plus usual practice
Number of subjects: 13638
Study 28422968 — intervention group
Group type: COMPARATOR
Intervention: Usual practice alone (control)
Number of subjects: 13638
Study 26728913 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted intervention
Number of subjects: 435
Study 26728913 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-assisted intervention
Number of subjects: 435
Study 26728913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 435
Study 24934845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including mailed reminder letter, free FIT with low-literacy instructions, automated telephone and text reminders, and personal telephone outreach.
Number of subjects: 450
Study 24934845 — intervention group
Group type: COMPARATOR
Intervention: Usual care including computerized reminders, standing orders for medical assistants, and clinician feedback.
Number of subjects: 450
Study 24934845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group completion rates: 10.2% prior to due date, 39.6% within 2 weeks, 24.0% within 2 to 13 weeks, 8.4% between 13 and 26 weeks.
Number of subjects: 450
Study 22672707 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-DEF (exercise followed by fasting)
Number of subjects: 8
Study 22672707 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-BAL (exercise followed by carbohydrate intake)
Number of subjects: 8
Study 22672707 — intervention group
Group type: COMPARATOR
Intervention: CON (inactive control trial)
Number of subjects: 8
Study 19067286 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (10 mg/kg, 5 mg/kg, and 5 mg/kg over 3 days)
Number of subjects: 136
Study 19067286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 16112120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable lipid intake >or=34.4 g/day
Number of subjects: 1251
Study 16112120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake >or=7.726 mg/day
Number of subjects: 1251
Study 16112120 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum HDL cholesterol concentration (for 10mg/dl increase)
Number of subjects: 1251
Study 16112120 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (for 1 year increase)
Number of subjects: 1251
Study 16112120 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (for 10 packs/year increase)
Number of subjects: 1251
Study 16112120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure (for 5 mmHg increase)
Number of subjects: 1251
Study 15472099 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vasospasm (EVSP)
Number of subjects: 3478
Study 15472099 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vasospasm (EVSP) severity
Number of subjects: 3478
Study 11775393 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS; Pulmicort Respules)
Number of subjects: 670
Study 11775393 — intervention group
Group type: COMPARATOR
Intervention: Conventional asthma therapy (CAT)
Number of subjects: 670
Study 11775393 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 670
Study 11775393 — intervention group
Group type: COMPARATOR
Intervention: CAT
Number of subjects: 670
Study 11775393 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS and CAT
Number of subjects: 670
Study 9690497 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) utilization in CABG
Number of subjects: 138
Study 9690497 — intervention group
Group type: COMPARATOR
Intervention: CABG without radial artery (RA)
Number of subjects: 138
Study 8352699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg)
Number of subjects: 10
Study 8352699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3669200 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) grafts
Number of subjects: 105
Study 3669200 — intervention group
Group type: COMPARATOR
Intervention: Human umbilical vein grafts
Number of subjects: 105
Study 3669200 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PTFE and umbilical vein grafts
Number of subjects: 105
Study 31759183 — intervention group
Group type: EXPERIMENTAL
Intervention: MGO Manuka Honey microemulsion eye cream applied to one eye overnight for 3 months
Number of subjects: 53
Study 31759183 — intervention group
Group type: EXPERIMENTAL
Intervention: MGO Manuka Honey microemulsion eye cream
Number of subjects: 53
Study 31759183 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 53
Study 29738271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8
Study 29738271 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CMIE)
Number of subjects: 8
Study 25740268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat 40 mg with a single dose of Levora‐28®
Number of subjects: 24
Study 25740268 — intervention group
Group type: COMPARATOR
Intervention: Levora‐28® alone
Number of subjects: 24
Study 24122191 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT) administered within 24 h to 48 h of burn injury
Number of subjects: 17
Study 24122191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 17
Study 20352374 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 54
Study 20352374 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 18984264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast for 8 weeks in addition to oral prednisolone for 14 days and budenoside nasal spray for 8 weeks
Number of subjects: 38
Study 18984264 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone for 14 days and budenoside nasal spray for 8 weeks (Control)
Number of subjects: 38
Study 15465071 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD patients (preanxiolytic treatment)
Number of subjects: 202
Study 15465071 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic-treated GAD patients
Number of subjects: 202
Study 15465071 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD patients after treatment
Number of subjects: 202
Study 15465071 — intervention group
Group type: COMPARATOR
Intervention: CD patients
Number of subjects: 202
Study 15465071 — intervention group
Group type: COMPARATOR
Intervention: KT patients
Number of subjects: 202
Study 11465435 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with intravenous injection of erythropoietin 600 lU/kg after each blood predonation
Number of subjects: 78
Study 11465435 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion without erythropoietin
Number of subjects: 78
Study 11465435 — intervention group
Group type: COMPARATOR
Intervention: Homologous transfusion (control group)
Number of subjects: 78
Study 9509446 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis for 3 hours started after contrast medium administration
Number of subjects: 30
Study 9509446 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 30
Study 8044451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (32 mg during open phase, 24 mg during double-blind phase)
Number of subjects: 22
Study 8044451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 22
Study 3056807 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human proinsulin (0.025, 0.05, 0.1 units/kg)
Number of subjects: 0
Study 3056807 — intervention group
Group type: COMPARATOR
Intervention: Biosynthetic human insulin (0.025, 0.05, 0.1 units/kg)
Number of subjects: 0
Study 15848568 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab added to cyclosporine microemulsion and mycophenolate mofetil
Number of subjects: 90
Study 15848568 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion and mycophenolate mofetil without basiliximab
Number of subjects: 90
Study 30328970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg mangosteen pericarp per day for 24 weeks
Number of subjects: 0
Study 30328970 — intervention group
Group type: COMPARATOR
Intervention: Placebo per day for 24 weeks
Number of subjects: 0
Study 28502528 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐paratyrosine (AMPT)
Number of subjects: 40
Study 28502528 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 40
Study 25412759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional virtual patient educational activity
Number of subjects: 72
Study 25412759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 24189367 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV
Number of subjects: 150
Study 24189367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21493761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight group
Number of subjects: 113
Study 21493761 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 19553647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation omitted
Number of subjects: 498
Study 19553647 — intervention group
Group type: COMPARATOR
Intervention: Historical controls received prophylactic cranial irradiation
Number of subjects: 498
Study 19553647 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (498 total)
Number of subjects: 498
Study 17040484 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) chewing gum, 5 mg, 2 pieces, twice a day for 3 months
Number of subjects: 31
Study 17040484 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (CHX-free), same usage instructions as CHX group
Number of subjects: 31
Study 15248205 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Activity Score (DAS) in the UMCN cohort
Number of subjects: 337
Study 15248205 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28 in the COBRA cohort
Number of subjects: 337
Study 15248205 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard deviation (SD) of the mean interval DAS in the UMCN cohort
Number of subjects: 337
Study 10789609 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical American diet high in saturated fat (37% energy from fat)
Number of subjects: 30
Study 10789609 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step 1 diet (30% energy from fat)
Number of subjects: 30
Study 10789609 — intervention group
Group type: EXPERIMENTAL
Intervention: Macadamia nut-based monounsaturated fat diet (37% energy from fat)
Number of subjects: 30
Study 9073005 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep inhalation
Number of subjects: 100
Study 9073005 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceful and deep inhalation
Number of subjects: 100
Study 8145398 — intervention group
Group type: EXPERIMENTAL
Intervention: UF-021 (0.12%)
Number of subjects: 158
Study 8145398 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5%)
Number of subjects: 158
Study 3519053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 250
Number of subjects: 89
Study 3519053 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix 320
Number of subjects: 89
Study 25904673 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 10
Study 24578289 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer program
Number of subjects: 150
Study 24578289 — intervention group
Group type: COMPARATOR
Intervention: Standard care with provider‐based counseling
Number of subjects: 150
Study 22251105 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 200
Study 22251105 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study 21268369 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study 18412958 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acid regurgitation
Number of subjects: 4902
Study 18412958 — intervention group
Group type: COMPARATOR
Intervention: Less frequent or no symptoms of gastro-oesophageal reflux
Number of subjects: 4902
Study 16215331 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (OxyContin)
Number of subjects: 104
Study 16215331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 11940291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose recombinant tissue-type plasminogen activator (rt-PA) thrombolysis
Number of subjects: 261
Study 11940291 — intervention group
Group type: COMPARATOR
Intervention: Primary coronary stenting
Number of subjects: 261
Study 9450711 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive trials
Number of subjects: 43708
Study 9450711 — intervention group
Group type: COMPARATOR
Intervention: Negative trials
Number of subjects: 43708
Study 9450711 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with significant results favoring any arm
Number of subjects: 43708
Study 9450711 — intervention group
Group type: COMPARATOR
Intervention: Trials with nonsignificant results
Number of subjects: 43708
Study 7650092 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH (Methylphenidate); specific dosage and duration not mentioned
Number of subjects: 0
Study 7650092 — intervention group
Group type: COMPARATOR
Intervention: Experimenter-absent condition; control group is normal controls
Number of subjects: 0
Study 2719748 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of muroctasin (H group)
Number of subjects: 131
Study 2719748 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of muroctasin (L group)
Number of subjects: 131
Study 2719748 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (C group)
Number of subjects: 131
Study 1174902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid 3 g taken six-hourly during menstruation
Number of subjects: 56
Study 1174902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as women not receiving aminocaproic acid)
Number of subjects: 56
Study 31618495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral taurine for 12 weeks
Number of subjects: 404
Study 31618495 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 404
Study 30789931 — intervention group
Group type: EXPERIMENTAL
Intervention: CROS/BiCROS
Number of subjects: 0
Study 30789931 — intervention group
Group type: EXPERIMENTAL
Intervention: soft-band BAHA
Number of subjects: 0
Study 30789931 — intervention group
Group type: COMPARATOR
Intervention: CROS/BiCROS and soft-band BAHA
Number of subjects: 0
Study 29141522 — intervention group
Group type: EXPERIMENTAL
Intervention: WALANT
Number of subjects: 40
Study 29141522 — intervention group
Group type: COMPARATOR
Intervention: LA/tourniquet
Number of subjects: 40
Study 25203506 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CHO maltodextrin (WASH)
Number of subjects: 12
Study 25203506 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric artificial sweetener (PLA)
Number of subjects: 12
Study 23681295 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of an actor lifting an object
Number of subjects: 0
Study 23681295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting an object with weight changes between 2 and 7 N
Number of subjects: 0
Study 20722531 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) plus anorganic bovine bone matrix (ABM) with synthetic cell‐binding peptide P‐15
Number of subjects: 18
Study 20722531 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) only
Number of subjects: 18
Study 19930587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64)
Number of subjects: 129
Study 19930587 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 65)
Number of subjects: 129
Study 16527639 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable appliance with palatal crib combined with high-pull chincup therapy
Number of subjects: 30
Study 16527639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 12950425 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients with gastro-oesophageal reflux disease or duodenal gastro-oesophageal reflux
Number of subjects: 38
Study 12950425 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 38
Study 16687507 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait reward sensitivity
Number of subjects: 0
Study 16687507 — intervention group
Group type: COMPARATOR
Intervention: Low trait reward sensitivity
Number of subjects: 0